These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28800947)

  • 81. [Diagnostics and treatment of giant cell arteritis].
    Kraemer M; Becker J; Bley TA; Steinbrecher A; Minnerup J; Hellmich B
    Nervenarzt; 2022 Aug; 93(8):819-827. PubMed ID: 34734295
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Development of intracranial vasculitis in giant cell arteritis during tocilizumab treatment.
    Naderi N
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):207-209. PubMed ID: 32359040
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Giant Cell Arteritis: Practical Pearls and Updates.
    Pradeep S; Smith JH
    Curr Pain Headache Rep; 2018 Jan; 22(1):2. PubMed ID: 29344777
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Update on giant cell arteritis.
    Sammel AM; Fraser CL
    Curr Opin Ophthalmol; 2018 Nov; 29(6):520-527. PubMed ID: 30138144
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Large vessel vasculitis: giant cell arteritis and Takayasu arteritis].
    Petitpierre S; Bart PA; Leimgruber A; Spertini F; Prior J; Spertini F
    Rev Med Suisse; 2007 Apr; 3(108):1056-60, 1062-3. PubMed ID: 17552258
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treatment of giant-cell arteritis, a literature review.
    Watelet B; Samson M; de Boysson H; Bienvenu B
    Mod Rheumatol; 2017 Sep; 27(5):747-754. PubMed ID: 27919193
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
    Espígol-Frigolé G; Corbera-Bellalta M; Planas-Rigol E; Lozano E; Segarra M; García-Martínez A; Prieto-González S; Hernández-Rodríguez J; Grau JM; Rahman MU; Cid MC
    Ann Rheum Dis; 2013 Sep; 72(9):1481-7. PubMed ID: 22993227
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Recent advances in the diagnosis and therapy of large vessel vasculitis.
    Keser G; Atagunduz P; Soy M
    Pol Arch Intern Med; 2022 Jun; 132(6):. PubMed ID: 35699647
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Targeting platelet-neutrophil interactions in giant-cell arteritis.
    Baldini M; Manfredi AA; Maugeri N
    Curr Pharm Des; 2014; 20(4):567-74. PubMed ID: 23565638
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.
    Koster MJ; Matteson EL; Warrington KJ
    Curr Opin Rheumatol; 2016 May; 28(3):211-7. PubMed ID: 26885650
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.
    Kermani TA; Warrington KJ; Cuthbertson D; Carette S; Hoffman GS; Khalidi NA; Koening CL; Langford CA; Maksimowicz-McKinnon K; McAlear CA; Monach PA; Seo P; Merkel PA; Ytterberg SR;
    J Rheumatol; 2015 Jul; 42(7):1213-7. PubMed ID: 25877501
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series.
    Seitz M; Reichenbach S; Bonel HM; Adler S; Wermelinger F; Villiger PM
    Swiss Med Wkly; 2011; 141():w13156. PubMed ID: 21243547
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspects].
    Chaigne-Delalande S; de Menthon M; Lazaro E; Mahr A
    Presse Med; 2012 Oct; 41(10):955-65. PubMed ID: 22940467
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?].
    Hellmich B
    Z Rheumatol; 2021 May; 80(4):322-331. PubMed ID: 33710440
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.
    Dejaco C; Brouwer E; Mason JC; Buttgereit F; Matteson EL; Dasgupta B
    Nat Rev Rheumatol; 2017 Oct; 13(10):578-592. PubMed ID: 28905861
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Giant cell arteritis: diagnosing and treating inflammatory disease in older adults.
    Azhar SS; Tang RA; Dorotheo EU
    Geriatrics; 2005 Aug; 60(8):26-30. PubMed ID: 16092890
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Fulminant alveolar hemorrhage: evolution of giant cell arteritis to ANCA-positive vasculitis?].
    Garrouste C; Sailler L; Astudillo L; Lavayssière L; Cointault O; Borel C; Bernard J; Arlet P
    Rev Med Interne; 2008 Mar; 29(3):232-5. PubMed ID: 17983690
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; De Miguel E; Prieto-Peña D; González-Gay MÁ; Hernández JL; Blanco R;
    Semin Arthritis Rheum; 2021 Apr; 51(2):387-394. PubMed ID: 33607384
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
    Cid MC; Ríos-Garcés R; Terrades-García N; Espígol-Frigolé G
    Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii17-iii27. PubMed ID: 32348525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.